重症肌無力診斷及治療的全球市場:預測(2022年～2028年)

全球重症肌無力診斷及治療的市場規模在預測期間(2022年～2028年)內預計將以7.9％的年複合成長率增長。提高對罕見病的認識將推動重症肌無力診斷和治療市場的增長。

本報告提供全球重症肌無力診斷及治療市場相關調查分析，提供市場概要，競爭情形，市場分析，企業簡介等系統性資訊。

目錄

第1章 報告概要

• 目前產業分析與成長可能性的展望
• COVID-19全球重症肌無力診斷及治療市場給予的影響
• 全球重症肌無力診斷及治療市場復甦情景
  • 調查方法與工具
  • 市場明細
    • 各市場區隔
    • 各地區

第2章 市場概要與洞察

• 調查範圍
• 分析師的洞察和目前市場趨勢
  • 主要調查結果
  • 推薦事項
  • 結論

第3章 競爭情形

• 主要企業分析
  • Alexion Pharmaceutical Inc.
  • AbbVie, Inc.
  • F. Hoffmann-La Roche, Ltd.
  • Grifols SA
  • Novartis AG
• 主要策略分析
• COVID-19對主要企業帶來的影響

第4章 市場區隔

• 全球重症肌無力診斷及治療市場:不同治療
  • 投藥
    • 膽鹼酯[酉每]抑制劑
    • 皮質類固醇
    • 免疫抑制劑
  • 手術
  • 其他
• 全球重症肌無力診斷及治療市場:診斷
  • Edrophonium檢驗
  • 血液檢驗
  • 肺功能檢驗
  • 電力診斷
  • 成像
  • 其他
• 全球重症肌無力診斷及治療市場:終端用戶
  • 醫院
  • 診所
  • 其他

第6章 地區分析

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 西班牙
  • 法國
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 全球其他地區

第7章 企業簡介

• Amneal Pharmaceuticals, Inc.
• Argenx SE
• Astellas Pharma, Inc.
• Avadel Pharmaceuticals PLC
• Bausch Health Companies Inc.
• Baxter International, Inc.
• CSL Behring
• CuraVac, Inc.
• GlaxoSmithKline plc
• Immunovant, Inc.
• Mitsubishi Tanabe Pharma Corp.
• Ra Pharmaceuticals, Inc.
• Takeda Pharmaceutical Co., Ltd.
• UCB Pharma
• Valeant Pharmaceuticals International, Inc.

Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Treatment (Medication, Surgery, and Others), by Diagnosis (Edrophonium Tests, Blood Tests, Pulmonary Function Tests, Electrodiagnostic, Imaging, and Others), and by End-Users (Hospitals, Clinics, and Others) Forecast Period (2022-2028)

The global MG diagnosis and treatment market is anticipated to grow at a substantial CAGR of 7.9% during the forecast period. Myasthenia gravis is a chronic autoimmune, neuromuscular disorder that leads to weakness in the skeletal muscles. The eyes, face, and swallowing tubes are the most affected muscles. Increasing awareness related to rare diseases is growing the market for global myasthenia gravis diagnosis and treatment. This disease is caused by an abnormal immune reaction (antibody-mediated autoimmune response) in which the body's immune defenses (i.e., antibodies) inappropriately attack certain proteins in muscles that receive nerve impulses. Factors such as antibodies and the thymus gland are predicted to be caused by myasthenia gravis. According to the Myasthenia Gravis Foundation Of America, around 14-20% of cases per 100,000 population in the US, which is around 36,000 to 60,000 cases in the US.

Impact of COVID-19 Pandemic on Global Myasthenia Gravis (MG) Diagnosis and Treatment Market

During the COVID-19 pandemic, limited transportation options and travel restrictions created hurdles to patients, international trade, and transportation, which disrupted the market for the myasthenia gravis diagnosis and treatment market. Patients' and doctors' footfall in the hospital declined during the pandemic which severely affected the patient's and myasthenia gravis diagnosis and treatment market. Many patients had faced challenges in getting proper medical care due to the pandemic. Diagnosis and treatment were majority put on hold at hospitals and diagnostics centers. Moreover, many manufacturers faced supply chain issues and hurdles during the pandemic.

Segmental Outlook

The global MG diagnosis and treatment market is segmented based on treatment, diagnosis, and end-users. Based on the treatment, the market is segmented into medication, surgery, and others. Based on the diagnosis, the market is sub-segmented into edrophonium tests, blood tests, pulmonary function tests, electrodiagnostic, imaging, and others. Further, based on the end-users, the market is augmented into hospitals, clinics, and others. Among the end-users, the hospitals are anticipated to hold a prominent market share. As patients mostly visit the hospital for diagnosis and treatment of the disease due to the presence of advanced equipment and proper guidance and consultation related to the disease.

Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Share by Treatment, 2021 (%)

Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Share by Treatment

The Medication Segment is Expected to Hold a Prominent Share in the Global Myasthenia Gravis (MG) Diagnosis and Treatment Market

The high intake of drugs to manage the associated symptoms of MG is a key factor contributing to the high market share of this market segment. Immunosuppressive drugs such as tacrolimus and cyclosporine and immunotherapies such as eculizumab and corticosteroids are the major medications taken by myasthenia gravis patients. The presence of a robust product pipeline of drugs used in the treatment of myasthenia gravis is anticipated to drive the growth of this market segment. For instance, IVIG treatment provides safe and effective long-term therapy for patients who are not benefited from conventional therapies.

Regional Outlooks

The global MG diagnosis and treatment market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. North America is anticipated to hold a considerable market share during the forecast period. High healthcare spending, the presence of cohesive government policies for R&D related to the myasthenia gravis treatment along with the presence of a huge patient pool are anticipated to be the key factors contributing to the high share of the North America region. According to the National Organization for Rare Disorders (NORD), in the US around 14-40 per 100,000 individuals suffer from myasthenia gravis on an annual basis. These factors will contribute to the growth of the market.

Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Growth, by Region 2022-2028

Global Myasthenia Gravis (MG) Diagnosis and Treatment Market Growth, by Region

Asia-Pacific Accounts to Register a Significant CAGR in the Global Myasthenia Gravis (MG) Diagnosis and Treatment Market

Asia-Pacific contributes a significant share of the global MG diagnosis and treatment market due to The rapidly evolving healthcare infrastructure, growing per capita healthcare expenditure, along with the presence of a huge targeted patient pool are anticipated to be the key factors driving the growth of the myasthenia gravis treatment market in the Asia-Pacific region. The growing awareness among the population of the emerging economies of the region related to autoimmune disorders such as myasthenia gravis and multiple sclerosis is anticipated to further drive the growth of the market in the region. According to OMICS International, In India, among the 1,065,070,607 population, 53,253 people are affected with Myasthenia Gravis.

Market Players Outlook

The major companies serving the global MG diagnosis and treatment market include Alexion Pharmaceutical Inc., Novartis AG, Grifols SA, F. Hoffmann-La Roche, Ltd., and others. The companies are focusing on product innovations, expansions, mergers, and acquisitions, partnerships, collaborations, and finding a new market or innovation in their core competency to expand individual market share. For instance, in November 2021, Siemens Healthineers launched the first CT scanner with photon-counting technology. Cleared for clinical use in the US and Europe, more than 20 systems were installed, over 8.000 patients scanned, and over 500 patents filed related to photon-counting.

The Report Covers

Market value data analysis of 2021 and forecast to 2028.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global myasthenia gravis (MG) diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

Current Industry Analysis and Growth Potential Outlook

Impact of COVID-19 on the Global Myasthenia Gravis Diagnosis and Treatment Market

Recovery Scenario of Global Myasthenia Gravis Diagnosis and Treatment Market

1.1.Research Methods and Tools

1.2.Market Breakdown

1.2.1.By Segments

1.2.2.By Region

2.Market Overview and Insights

2.1.Scope of the Report

2.2.Analyst Insight & Current Market Trends

2.2.1.Key Findings

2.2.2.Recommendations

2.2.3.Conclusion

3.Competitive Landscape

3.1.Key Company Analysis

3.1.1.Alexion Pharmaceutical Inc.

3.1.1.1.Overview

3.1.1.2.Financial Analysis

3.1.1.3.SWOT Analysis

3.1.1.4.Recent Developments

3.1.2.AbbVie, Inc.

3.1.2.1.Overview

3.1.2.2.Financial Analysis

3.1.2.3.SWOT Analysis

3.1.2.4.Recent Developments

3.1.3.F. Hoffmann-La Roche, Ltd.

3.1.3.1.Overview

3.1.3.2.Financial Analysis

3.1.3.3.SWOT Analysis

3.1.3.4.Recent Developments

3.1.4.Grifols SA

3.1.4.1.Overview

3.1.4.2.Financial Analysis

3.1.4.3.SWOT Analysis

3.1.4.4.Recent Developments

3.1.5.Novartis AG

3.1.5.1.Overview

3.1.5.2.Financial Analysis

3.1.5.3.SWOT Analysis

3.1.5.4.Recent Developments

3.2.Key Strategy Analysis

3.3.Impact of COVID-19 on Key Players

4.Market Segmentation

4.1.Global Myasthenia Gravis Diagnosis and Treatment Market by Treatment

4.1.1.Medication

4.1.1.1.Cholinesterase Inhibitors

4.1.1.2.Corticosteroids

4.1.1.3.Immunosuppressants

4.1.2.Surgery

4.1.3.Others

4.2.Global Myasthenia Gravis Diagnosis and Treatment Market By Diagnosis

4.2.1.Edrophonium Tests

4.2.2.Blood Tests

4.2.3.Pulmonary Function Tests

4.2.4.Electrodiagnostic

4.2.5.Imaging

4.2.6.Others

4.3.Global Myasthenia Gravis Diagnosis and Treatment Market by End-Users

4.3.1.Hospitals

4.3.2.Clinics

4.3.3.Other

5.Regional Analysis

5.1.North America

5.1.1.US

5.1.2.Canada

5.2.Europe

5.2.1.UK

5.2.2.Germany

5.2.3.Italy

5.2.4.Spain

5.2.5.France

5.2.6.Rest of Europe

5.3.Asia-Pacific

5.3.1.China

5.3.2.India

5.3.3.Japan

5.3.4.South Korea

5.3.5.Rest of Asia-Pacific

5.4.Rest of the World

6.Company Profiles

6.1.Amneal Pharmaceuticals, Inc.

6.2.Argenx SE

6.3.Astellas Pharma, Inc.

6.4.Avadel Pharmaceuticals PLC

6.5.Bausch Health Companies Inc.

6.6.Baxter International, Inc.

6.7.CSL Behring

6.8.CuraVac, Inc.

6.9.GlaxoSmithKline plc

6.10.Immunovant, Inc.

6.11.Mitsubishi Tanabe Pharma Corp.

6.12.Ra Pharmaceuticals, Inc.

6.13.Takeda Pharmaceutical Co., Ltd.

6.14.UCB Pharma

6.15.Valeant Pharmaceuticals International, Inc.

LIST OF TABLES

1.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)

2.GLOBAL MEDICATION FOR MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

3.GLOBAL SURGERY MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

4.GLOBAL OTHER FOR MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

5.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)

6.GLOBAL EDROPHONIUM TESTS IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

7.GLOBAL BLOOD TESTS IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

8.GLOBAL PULMONARY FUNCTION TESTS IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

9.GLOBAL ELECTRODIAGNOSTIC IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

10.GLOBAL IMAGING IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

11.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)

12.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

13.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

14.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT IN OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)

15.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)

16.NORTH AMERICA MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)

17.NORTH AMERICAN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)

18.NORTH AMERICAN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)

19.NORTH AMERICAN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)

20.EUROPEAN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)

21.EUROPEAN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)

22.EUROPEAN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)

23.EUROPEAN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)

24.ASIA-PACIFIC MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)

25.ASIA-PACIFIC MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)

26.ASIA-PACIFIC MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)

27.ASIA-PACIFIC MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)

28.REST OF THE WORLD MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)

29.REST OF THE WORLD MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2021-2028 ($ MILLION)

31.REST OF THE WORLD MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY END-USERS, 2021-2028 ($ MILLION)

LIST OF FIGURES

1.IMPACT OF COVID-19 ON GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET, 2021-2028 ($ MILLION)

2.IMPACT OF COVID-19 ON GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)

3.RECOVERY OF GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET, 2022-2028 (%)

4.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY TREATMENT, 2021 VS 2028 (%)

5.GLOBAL MEDICATION FOR MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

6.GLOBAL SURGERY MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

7.GLOBAL OTHER FOR MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

8.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY DIAGNOSIS, 2021 VS 2028 (%)

9.GLOBAL EDROPHONIUM TESTS IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

10.GLOBAL BLOOD TESTS IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

11.GLOBAL PULMONARY FUNCTION TESTS IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

12.GLOBAL ELECTRODIAGNOSTIC IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

13.GLOBAL IMAGING IN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

14.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY END-USERS, 2021 VS 2028 (%)

15.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT IN HOSPITALS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

16.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT IN CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

17.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT IN OTHER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

18.GLOBAL MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)

19.US MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

20.CANADA MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

21.UK MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

22.FRANCE MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

23.GERMANY MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

24.ITALY MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

25.SPAIN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

26.REST OF EUROPE MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

27.INDIA MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

28.CHINA MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

29.JAPAN MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

30.SOUTH KOREA MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

31.REST OF ASIA-PACIFIC MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)

32.REST OF THE WORLD MYASTHENIA GRAVIS DIAGNOSIS AND TREATMENT MARKET SIZE, 2021-2028 ($ MILLION)